HER-2-mediated endocytosis of magnetic nanospheres and the implications in cell targeting and particle magnetization.

Polypyrrole-Fe3O4 nanospheres were synthesized via an emulsion polymerization method with hyaluronic acid as the surfactant. Hyaluronic acid offers the advantages of biocompatibility, cell adhesive property and the availability of functional groups for attachment of other molecules. The nanospheres were further functionalized with herceptin, and the efficacy of uptake of the functionalized nanospheres by human breast cancer cells was evaluated. It is envisioned that the combination of hyaluronic acid with its cell adhesive property and herceptin would result in high efficacy of internalization of the nanospheres by the cancer cells via a HER-2-mediated endocytosis. Our results showed that this is indeed the case and that the high concentration of herceptin-functionalized magnetic nanospheres in the cancer cells offers great potential in cancer cell targeting and treatment. In addition, the magnetic property of these nanospheres was also critically investigated and the magnetization was found to be affected by the particles' environment. The combination of these cell-targeting magnetic carriers with chemotherapeutic agents will be highly advantageous for the preferential killing of cancer cells in hyperthermia treatment.

[1]  M. Tammi,et al.  Hyaluronan-Cell Interactions in Cancer and Vascular Disease* , 2002, The Journal of Biological Chemistry.

[2]  Jaakko Astola,et al.  Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines , 2004, Oncogene.

[3]  T. Sawada,et al.  Antitumor Effect of Trastuzumab for Pancreatic Cancer with High HER-2 Expression and Enhancement of Effect by Combined Therapy with Gemcitabine , 2006, Clinical Cancer Research.

[4]  Urs O. Häfeli,et al.  Scientific and clinical applications of magnetic carriers , 1997 .

[5]  G Brockhoff,et al.  Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK‐BR‐3 breast cancer cell proliferation , 2007, Cell proliferation.

[6]  J. Comyn.  High resolution XPS of organic polymers The Scienta ESCA300 Database , 1993 .

[7]  Development of anti-p 185 IER 2 immunoliposomes for cancer therapy , 2005 .

[8]  M. Cobleigh,et al.  Targeting metastatic and advanced breast cancer. , 2007, Seminars in oncology nursing.

[9]  Q. Pankhurst,et al.  Applications of magnetic nanoparticles in biomedicine , 2003 .

[10]  V. Hascall,et al.  Hyaluronan and tumor growth. , 2002, The American journal of pathology.

[11]  R. Nahta,et al.  Herceptin: mechanisms of action and resistance. , 2006, Cancer letters.

[12]  S. Mørup.  Mössbauer spectroscopy studies of suspensions of Fe3O4 microcrystals , 1983 .

[13]  John W. Park,et al.  Development of anti-p185HER2 immunoliposomes for cancer therapy. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. Pober,et al.  Four different classes of inhibitors of receptor-mediated endocytosis decrease tumor necrosis factor-induced gene expression in human endothelial cells. , 1993, Journal of immunology.

[15]  Hiroyuki Honda,et al.  Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia. , 2004, Cancer Letters.

[16]  R. Nahta,et al.  HER-2-targeted therapy: lessons learned and future directions. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  C. Chauzy,et al.  Hyaluronan: fundamental principles and applications in cancer , 1997, Journal of internal medicine.

[18]  C. Alexiou,et al.  Locoregional cancer treatment with magnetic drug targeting. , 2000, Cancer research.

[19]  Alex I. Braginski,et al.  The SQUID handbook , 2006 .

[20]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[21]  S. Ylä-Herttuala,et al.  Targeted magnetic resonance imaging of Scavidin‐receptor in human umbilical vein endothelial cells in vitro , 2006, Magnetic resonance in medicine.

[22]  M. Gumbleton,et al.  Endocytosis at the blood–brain barrier: From basic understanding to drug delivery strategies , 2006, Journal of drug targeting.

[23]  K. Strebhardt,et al.  Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells. , 2006, Biomaterials.

[24]  Ivo Safarik,et al.  Overview of Magnetic Separations Used in Biochemical and Biotechnological Applications , 1997 .

[25]  W. Stickle,et al.  Handbook of X-Ray Photoelectron Spectroscopy , 1992 .

[26]  E. Kleinerman,et al.  Herceptin Down-Regulates HER-2/neu and Vascular Endothelial Growth Factor Expression and Enhances Taxol-Induced Cytotoxicity of Human Ewing's Sarcoma Cells In vitro and In vivo , 2005, Clinical Cancer Research.

[27]  A. Ullrich,et al.  Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. , 1990, Cancer research.

[28]  D. Slamon,et al.  Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. , 2004, Journal of the National Cancer Institute.

[29]  J. Vilček,et al.  Tumor necrosis factor: specific binding and internalization in sensitive and resistant cells. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Christoph Alexiou,et al.  Targeting cancer cells: magnetic nanoparticles as drug carriers , 2006, European Biophysics Journal.

[31]  D. Leckband,et al.  Synthesis and functionalization of polypyrrole-Fe3O4 nanoparticles for applications in biomedicine , 2007 .

[32]  H. Chung,et al.  Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. , 2004, Cancer letters.

[33]  P. Prehm.  Synthesis of hyaluronate in differentiated teratocarcinoma cells. Mechanism of chain growth. , 1983, The Biochemical journal.

[34]  A. Ullrich,et al.  Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. , 1991, Growth regulation.

[35]  K. Neoh,et al.  Cellular response to magnetic nanoparticles "PEGylated" via surface-initiated atom transfer radical polymerization. , 2006, Biomacromolecules.

[36]  T. E. Haynes,et al.  Oriented, single domain Fe nanoparticle layers in single crystal yttria-stabilized zirconia , 2001 .

[37]  Jin-Sil Choi,et al.  In vivo magnetic resonance detection of cancer by using multifunctional magnetic nanocrystals. , 2005, Journal of the American Chemical Society.

[38]  Ami E. Berkowitz,et al.  Properties of magnetic fluid particles , 1980 .

[39]  M. Barberi-Heyob,et al.  In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2-expressing human breast cancer cell lines. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  B. Chu,et al.  Preparation and Properties of Magnetite and Polymer Magnetite Nanoparticles , 1999 .

[41]  Dmitri Artemov,et al.  MR molecular imaging of the Her‐2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles , 2003, Magnetic resonance in medicine.

[42]  T. Waldmann,et al.  Herceptin-Geldanamycin Immunoconjugates , 2004, Cancer Research.

[43]  Douglas Lauffenburger,et al.  Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: quantitative analysis of HER2 overexpression effects. , 2003, Cancer research.

[44]  D. Leckband,et al.  Polypyrrole nanospheres with magnetic and cell-targeting capabilities , 2007 .